Leerink Partnrs Issues Negative Outlook for Geron Earnings

Geron Co. (NASDAQ:GERN) – Equities research analysts at Leerink Partnrs decreased their Q2 2025 EPS estimates for Geron in a research note issued on Thursday, November 7th. Leerink Partnrs analyst F. Khurshid now expects that the biopharmaceutical company will post earnings per share of $0.01 for the quarter, down from their prior estimate of $0.02. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.34) per share. Leerink Partnrs also issued estimates for Geron’s Q4 2025 earnings at $0.06 EPS, FY2025 earnings at $0.10 EPS and FY2026 earnings at $0.33 EPS.

Geron (NASDAQ:GERN) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. The business had revenue of $28.27 million during the quarter, compared to the consensus estimate of $18.97 million. Geron had a negative return on equity of 67.10% and a negative net margin of 682.48%. The company’s quarterly revenue was up 17138.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.08) EPS.

A number of other research firms also recently issued reports on GERN. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Geron in a report on Friday, August 9th. StockNews.com raised shares of Geron to a “sell” rating in a research report on Monday, August 5th. Scotiabank started coverage on shares of Geron in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 target price on the stock. HC Wainwright assumed coverage on Geron in a report on Tuesday, November 5th. They issued a “buy” rating and a $8.00 target price for the company. Finally, Wedbush reiterated an “outperform” rating and set a $8.00 price target on shares of Geron in a report on Thursday, August 8th. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.05.

Geron Stock Down 3.6 %

Shares of NASDAQ:GERN opened at $3.97 on Monday. The business’s 50 day moving average is $4.29 and its 200 day moving average is $4.32. Geron has a 12-month low of $1.64 and a 12-month high of $5.34. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of -12.41 and a beta of 0.52. The company has a quick ratio of 3.60, a current ratio of 3.61 and a debt-to-equity ratio of 0.12.

Institutional Investors Weigh In On Geron

Large investors have recently added to or reduced their stakes in the company. Arizona State Retirement System increased its stake in shares of Geron by 3.1% in the second quarter. Arizona State Retirement System now owns 115,400 shares of the biopharmaceutical company’s stock worth $489,000 after purchasing an additional 3,465 shares in the last quarter. Values First Advisors Inc. raised its holdings in Geron by 13.6% during the 3rd quarter. Values First Advisors Inc. now owns 30,674 shares of the biopharmaceutical company’s stock valued at $139,000 after acquiring an additional 3,668 shares during the period. CIBC Asset Management Inc lifted its position in shares of Geron by 32.7% during the second quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 3,805 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Geron by 23.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 4,094 shares during the period. Finally, SG Americas Securities LLC grew its position in shares of Geron by 32.6% in the third quarter. SG Americas Securities LLC now owns 22,630 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 5,559 shares in the last quarter. Hedge funds and other institutional investors own 73.71% of the company’s stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.